192 related articles for article (PubMed ID: 37804164)
1. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
[TBL] [Abstract][Full Text] [Related]
2. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
[TBL] [Abstract][Full Text] [Related]
3. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
4. High expression ITGA2 affects the expression of MET, PD-L1, CD4 and CD8 with the immune microenvironment in pancreatic cancer patients.
Jin L; Duan Y; Li X; Li Z; Hu J; Shi H; Su Z; Li Z; Du B; Chen Y; Tan Y
Front Immunol; 2023; 14():1209367. PubMed ID: 37881431
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
9. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
[TBL] [Abstract][Full Text] [Related]
10. FOXA1/UBE2T Inhibits CD8
Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
Yang J; Chen J; Liang H; Yu Y
Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression.
Li B; Wang B
Immunol Invest; 2022 Oct; 51(7):1921-1937. PubMed ID: 35852892
[TBL] [Abstract][Full Text] [Related]
19. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
20. Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma.
Gao Q; Liu HT; Xu YQ; Zhang L; Liu YR; Ren Q; Sheng JP; Zhang ZX
Cancer Cell Int; 2021 Oct; 21(1):584. PubMed ID: 34717645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
